Clinical Trials IMPACT

RECRUITMENT COMPLETED – AWAITING RESULTS

The IMPACT trial investigates a very specific and novel immunotherapy called Imotopes™ that has the potential to stop the progression of type 1 diabetes. The treatment was already administered in a first clinical trial and showed a good safety profile. This second study is testing two doses of Imotope™ in newly diagnosed adult (18-44 years) patients to evaluate efficacy on stopping the loss of the beta cell. Participants received 6 initial administrations of the treatment and 1 additional boost administration. People taking part in the trial are being followed for up to 2 years. The recruitment in the study is now completed.